What is it about?
This research investigates the biological connection between Chronic Periodontitis (CP) and Coronary Heart Disease (CHD), focusing on serum Asymmetric Dimethylarginine (ADMA) as a shared biochemical mediator of endothelial dysfunction. Periodontitis is a chronic inflammatory disorder caused by oral bacterial biofilms, which trigger systemic immune responses and release pro-inflammatory cytokines into the bloodstream. These systemic signals disrupt normal blood vessel lining (endothelium) health. ADMA acts as an endogenous inhibitor of Nitric Oxide Synthase (NOS), the enzyme responsible for producing nitric oxide (NO)—a key molecule essential for vascular relaxation, blood flow regulation, and anti-inflammatory vessel defense. Elevated ADMA levels suppress NO production, impairing vascular dilation and directly accelerating endothelial dysfunction, an early hallmark of atherosclerosis and CHD. By analyzing serum ADMA concentrations across patient groups—including individuals with CP alone, CHD alone, both conditions combined, and healthy controls—this study aims to determine whether severity of periodontal disease correlates with higher circulating ADMA and impaired vascular health. Demonstrating a direct association among ADMA, periodontitis, and endothelial dysfunction would validate ADMA as a potential biomarker linking oral infection to cardiovascular risk. Ultimately, the findings aim to emphasize the clinical importance of treating periodontal inflammation as a modifiable risk factor to improve vascular endothelial function and reduce cardiovascular complications in high-risk populations.
Featured Image
Photo by Danielle-Claude Bélanger on Unsplash
Why is it important?
Both Chronic Periodontitis (CP) and Coronary Heart Disease (CHD) are prevalent chronic inflammatory conditions globally. There is underrecognized oral-systemic link established in terms of these diseases. Periodontitis isn't just an oral health problem but the systemic inflammation caused by gum disease significantly impacts vascular health. Asymmetric Dimethylarginine (ADMA) is a natural inhibitor of nitric oxide production, making it a critical biomarker for endothelial dysfunction (the precursor to atherosclerosis). Understanding ADMA levels could help identify high-risk heart patients early during routine dental evaluations.
Perspectives
1. Clinical & Preventive Perspective This research highlights oral care as an integral component of overall cardiovascular risk management. It offers cardiologists and periodontists a potential serum biomarker (ADMA) for collaborative diagnostic screening. 2. Pathophysiological Perspective Explores the mechanistic bridge (endothelial dysfunction via the ADMA-Nitric Oxide pathway) linking localized periodontal inflammation to systemic vascular disease. 3. Public Health Perspective Promotes interdisciplinary healthcare strategies (integrating dentistry and cardiology) to lower chronic disease burden in communities.
Afsheen Rizvi
Read the Original
This page is a summary of: Association of Serum ADMA with Endothelial Dysfunction in Chronic Periodontitis and Coronary Heart Disease Patients, Current Hypertension Reviews, August 2026, Bentham Science Publishers,
DOI: 10.2174/0115734021434691260120091010.
You can read the full text:
Contributors
The following have contributed to this page
